Corp) reported its Q4 2024 earnings, revealing a significant miss on Wall Street expectations. The company posted an earnings ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.

Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...

Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying ...

Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Shinhan Financial shows promise with increased non-interest income and lower credit costs. Find out why SHG stock is a Buy ...

Union Minister of Labour and Employment Mansukh Mandaviya has been taking regular meetings with EPFO officials to review the ...